New Drugs for Ankylosing Spondylitis Treatment Coming Down the Pipeline: An Updated Clinical Status by DelveInsight
Around 30+ notable companies are developing Ankylosing Spondylitis therapies. There are currently many new or repurposed drugs in clinical trials being tested to determine clinical benefits in Ankylosing Spondylitis patients.
Los Angeles, USA, April 15, 2021 (GLOBE NEWSWIRE) -- New Drugs for Ankylosing Spondylitis Treatment Coming Down the Pipeline: An Updated Clinical Status by DelveInsight
Around 30+ notable companies are developing Ankylosing Spondylitis therapies. There are currently many new or repurposed drugs in clinical trials being tested to determine clinical benefits in Ankylosing Spondylitis patients.
DelveInsight’s “Ankylosing Spondylitis (Bekhterev's Disease) Pipeline Insight” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Ankylosing Spondylitis pipeline landscapes. It comprises Ankylosing Spondylitis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Ankylosing Spondylitis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Ankylosing Spondylitis pipeline products.
Some of the key takeaways of the Ankylosing Spondylitis Pipeline Report
- Approximately 30+ key companies are developing Ankylosing Spondylitis therapies. These key players are Pfizer, UCB Biopharma, Hetero Biopharma, Amgen, Cadila Pharmaceuticals, Torrent Pharmaceuticals, Cipla, Emcure Pharmaceuticals, Boehringer Ingelheim, Zhejiang Hisun Pharmaceuticals, Biocad, AbbVie, Mycenax Biotech, Celltrion, Gilead Sciences, Amgen, Sun Pharma Global, Jiangsu HengRui Medicine Co., Ltd., Izana Bioscience, Suzhou Zelgen Biopharmaceuticals, Iltoo Pharma, Kinevant Sciences, Qyuns Therapeutics, Akeso Biopharma, Nimbus Therapeutics, Enzene Biosciences, Xbrane Biopharma, Dice molecules, and others have their Ankylosing Spondylitis drug candidates in the different phases of clinical development.
- Pfizer is one of the companies whose Ankylosing Spondylitis drug candidate is in the most advanced stage (Preregistration). Its drug candidate is Tofacitinib, a medication used to treat Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis.
- UCB Biopharma is developing Bimekizumab, an investigational humanised monoclonal IgG1 antibody that is in Phase III of a clinical trial.
- In October 2020, Jiangsu HengRui initiated Phase II/III studies to evaluate the efficacy and safety of SHR0302 in patients With Ankylosing Spondylitis (NCT04481139).
Get an overview of pipeline landscape @ New Drugs for Ankylosing Spondylitis
Ankylosing Spondylitis is a form of arthritis that primarily affects the spine. It causes severe inflammation of the spinal joints that can lead to chronic pain and discomfort. The disease can also cause pain, inflammation in other parts of the body, such as the shoulders, hips, ribs, heels and small joints of the hands and feet. In some cases, the eyes are also involved.
Ankylosing Spondylitis Emerging Drugs
- Tofacitinib: Pfizer
Tofacitinib, sold under the brand Xeljanz, is a medication used to treat Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis. Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs.
- Bimekizumab: UCB Biopharma
Bimekizumab is an investigational humanised monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F. Bimekizumab binds to and neutralises IL-17A and IL-17F, preventing their interactions with the IL-17 receptors expressed on keratinocytes, fibroblast-like synoviocytes, endothelial cells, chondrocytes and osteoblasts.
For further information, refer to the detailed report @ Ankylosing Spondylitis Pipeline Therapeutics
Scope of Ankylosing Spondylitis Pipeline Drug Insight
- Coverage: Global
- Major Players: 30+ Key Players
- Prominent Players: Pfizer, UCB Biopharma, Fresenius Kabi, Shanghai Henlius Biotech, Fujifilm Kyowa Kirin Biologics, Hetero Biopharma, Bio-Thera Solutions, Amgen, CinnaGen, Zydus cedilla, Cadila Pharmaceuticals, Sandoz, Innovent Biologics, Torrent Pharmaceuticals, Cipla, Emcure Pharmaceuticals, Biogen, Boehringer Ingelheim, Zhejiang Hisun Pharmaceuticals, Biocad, AbbVie, Mycenax Biotech, Celltrion, Gilead Sciences, Amgen, Sun Pharma Global, Jiangsu HengRui Medicine Co., Ltd., Izana Bioscience, Suzhou Zelgen Biopharmaceuticals, Iltoo Pharma, Kinevant Sciences, Qyuns Therapeutics, Akeso Biopharma, Nimbus Therapeutics, Enzene Biosciences, Xbrane Biopharma, Dice molecules, and many others.
- Key Drugs Profiles: 30+ Products
- Phases:
- Ankylosing Spondylitis Therapies Late-stage (Phase III)
- Ankylosing Spondylitis Therapies Mid-stage (Phase II)
- Ankylosing Spondylitis Therapies Early-stage (Phase I)
- Ankylosing Spondylitis Pre-clinical stage and Discovery candidates
- Discontinued and Inactive candidates
- Molecule Types:
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Peptides
- Polymer
- Route of Administration:
- Oral
- Subcutaneous
- Intramuscular
- Topical
- Intravenous
- Product Types:
- Monotherapy
- Combination
- Mono/Combination
Key Questions regarding Current Ankylosing Spondylitis Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
- What are the current options for Ankylosing Spondylitis treatment?
- How many companies are developing therapies for the treatment of Ankylosing Spondylitis?
- How many are Ankylosing Spondylitis emerging therapies in the early-stage, mid-stage, and late development stages to treat Ankylosing Spondylitis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Ankylosing Spondylitis market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of Ankylosing Spondylitis?
- What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Ankylosing Spondylitis therapies?
- What are the critical designations that have been granted for the emerging therapies for Ankylosing Spondylitis?
- How many patents are granted and pending for the emerging therapies to treat Ankylosing Spondylitis?
Table of Contents
| 1 | Ankylosing Spondylitis Report Introduction |
| 2 | Ankylosing Spondylitis Executive Summary |
| 3 | Ankylosing Spondylitis Overview |
| 4 | Ankylosing Spondylitis Pipeline Therapeutics |
| 5 | Ankylosing Spondylitis Therapeutic Assessment |
| 6 | Ankylosing Spondylitis – DelveInsight’s Analytical Perspective In-depth Commercial Assessment |
| 7 | Ankylosing Spondylitis Late Stage Products (Registered/Launch) |
| 7.1 | MSB11022: Fresenius Kabi |
| 8 | Ankylosing Spondylitis Late Stage Products (Preregistration) |
| 8.1 | Tofacitinib: Pfizer |
| 9 | Ankylosing Spondylitis Late Stage Products (Phase III) |
| 9.1 | Bimekizumab: UCB Biopharma |
| 10 | Ankylosing Spondylitis Mid Stage Products (Phase II/III) |
| 10.1 | Tildrakizumab: Sun Pharma Global |
| 11 | Ankylosing Spondylitis Mid Stage Products (Phase II) |
| 11.1 | Namilumab: Izana Bioscience |
| 12 | Ankylosing Spondylitis Early Stage Products (Phase I) |
| 12.1 | KIN-1901: Kinevant Sciences |
| 13 | Ankylosing Spondylitis Preclinical Stage Products |
| 13.1 | Xcimzane: Xbrane Biopharma |
| 14 | Ankylosing Spondylitis Discovery Stage Products |
| 14.1 | DNA-encoded library (DEL) technology: Dice molecules |
| 15 | Ankylosing Spondylitis Inactive Products |
| 16 | Ankylosing Spondylitis Key Companies |
| 17 | Ankylosing Spondylitis Key Products |
| 18 | Ankylosing Spondylitis Unmet Needs |
| 19 | Ankylosing Spondylitis Market Drivers and Barriers |
| 20 | Ankylosing Spondylitis Future Perspectives and Conclusion |
| 21 | Ankylosing Spondylitis Analyst Views |
| 22 | Appendix |
| 23 | About DelveInsight |
Get a customised pipeline report @ Ankylosing Spondylitis Drugs Pipeline Report
Related Reports
DelveInsight's Ankylosing Spondylitis (Bekhterev's Disease) - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Ankylosing Spondylitis (Bekhterev's Disease) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight's Ankylosing Spondylitis Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Hypertrophic Scar - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of the disease.
Myc Proto-Oncogene Protein Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario.
DelveInsight's Hepatic Impairment- Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview and in-depth understanding of Hepatic Impairment.
DelveInsight's Pertussis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of the Pertussis Market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us: Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com
